Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

POLARIS: PALBOCICLIB IN HORMONE RECEPTOR POSITIVE ADVANCED BREAST CANCER: A PROSPECTIVE MULTICENTER NON-INTERVENTIONAL STUDY

NCT03280303 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT03280303
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03280303 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
POLARIS: PALBOCICLIB IN HORMONE RECEPTOR POSITIVE ADVANCED BREAST CANCER: A PROSPECTIVE MULTICENTER NON-INTERVENTIONAL STUDY
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
January 4, 2017
Completion date
December 22, 2022
Enrollment
1,285 (actual)
Sites
305

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer, metastatic breast cancer